Other equities research analysts have also recently issued research reports about the company. Zacks Investment Research cut Oxford Immunotec Global from a buy rating to a hold rating in a research note on Tuesday, March 19th. ValuEngine lowered Oxford Immunotec Global from a strong-buy rating to a buy rating in a report on Tuesday, March 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. Oxford Immunotec Global presently has an average rating of Hold and a consensus target price of $18.00.
OXFD stock traded up $0.03 during midday trading on Friday, hitting $13.79. The company’s stock had a trading volume of 442,500 shares, compared to its average volume of 176,130. Oxford Immunotec Global has a 52-week low of $11.66 and a 52-week high of $19.19. The firm has a 50-day moving average of $14.72. The company has a market cap of $366.33 million, a price-to-earnings ratio of 27.04 and a beta of 0.35. The company has a quick ratio of 12.03, a current ratio of 12.60 and a debt-to-equity ratio of 0.04.
In other news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $16.05, for a total value of $48,150.00. Following the transaction, the director now directly owns 3,000 shares in the company, valued at approximately $48,150. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 4.21% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. FIL Ltd acquired a new position in shares of Oxford Immunotec Global in the first quarter valued at approximately $5,586,000. Martingale Asset Management L P acquired a new stake in shares of Oxford Immunotec Global during the fourth quarter worth $1,499,000. Bellevue Group AG lifted its holdings in shares of Oxford Immunotec Global by 38.2% during the fourth quarter. Bellevue Group AG now owns 306,606 shares of the company’s stock worth $3,918,000 after buying an additional 84,769 shares in the last quarter. EAM Global Investors LLC acquired a new stake in shares of Oxford Immunotec Global during the first quarter worth $1,330,000. Finally, Marshall Wace LLP acquired a new stake in shares of Oxford Immunotec Global during the first quarter worth $1,185,000. 91.57% of the stock is currently owned by institutional investors.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Featured Story: Diversification For Individual Investors
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.